HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer
- PMID: 37863030
- DOI: 10.1016/j.chembiol.2023.08.006
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer
Abstract
Inhibitors for the KAT6 family of histone acetyltransferases (HATs) have been actively pursued due to the oncogenic roles of KAT6A in human cancer. CTx-648 is a novel KAT6A/B inhibitor with excellent pharmacokinetic properties and in vivo efficacy that represents a promising new treatment strategy for estrogen-receptor-positive breast cancer.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare competing financial interests: K.P. serves on the scientific advisory board of Novartis, Vividion Therapeutics, Ideya Biosciences, and Scorpion Therapeutics; holds equity options in Scorpion Therapeutics and Ideya Biosciences; and receives sponsored research funding through Dana-Farber from Novartis. R.J. received research funding (institutional) from Pfizer and Lilly and is a consultant for Carrick Therapeutics and GE Health.
Comment on
-
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.Cell Chem Biol. 2023 Oct 19;30(10):1191-1210.e20. doi: 10.1016/j.chembiol.2023.07.005. Epub 2023 Aug 8. Cell Chem Biol. 2023. PMID: 37557181
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical